Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU) - AECUDATT

Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin0 个研究点目标入组 30 人开始时间: 2009年1月26日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Informed consent signed and dated
•Reliable method of contraception for both women of childbearing potential as well as man during the study and 3 months thereafter. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner
•Outpatients with ACU for more than 6 weeks. Urticaria symptoms must comprise wheal and itch.
•Age between 18 and 75 years.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Subjects who are inmates of psychiatric wards, prisons, or other state institutions. Existing or planned placement in an institution after ruling according to § 40 passage 1 number 4 AMG (Arzneimittelgesetz).
•The presence of permanent severe diseases, especially those affecting the immune system, except urticaria and cold urticaria
•The presence of permanent gastrointestinal condition which may influence the oral therapy (chronic diarrhoea diseases, congenital malformations or surgical mutilations of gastrointestinal tract)
•History or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia
•History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy
•Evidence of severe renal dysfunction
•Evidence of significant hepatic disease (liver enzymes twice the upper reference value)
•History of adverse reactions to DL
•Presence of active cancer which requires chemotherapy or radiation therapy
•Presence of alcohol abuse or drug addiction
•Intake of oral corticosteroids within 14 days prior to screening visit
•Use of depot corticosteroids or chronic systemic corticosteroids within 21 days prior to screening visit
•Use of systemic immunosupressants/immunomodulators like ciclosporine A, dapsone, methotrexate, mycophenolate, chloroquine, and comparable drugs within 28 days prior to screening visit.
•Pregnancy or breast-feeding

发起方

Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin